Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Dec 1;34(12):2052-2053.
doi: 10.1681/ASN.0000000000000231.

Authors' Reply: Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation?

Norberto Perico  1 , Matthew D Griffin  2 , Federica Casiraghi  1 , Giuseppe Remuzzi  1
Affiliations
Comment

Authors' Reply: Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation?

Norberto Perico et al. J Am Soc Nephrol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

M.D. Griffin reports honoraria from the American Society of Nephrology, Hebei Medical University, China, National Institutes of Health (NIDDK), Novo Nordisk, and Théa Pharma Ltd., Ireland; Research Funding: Orbsen Therapeutics Ltd.; and advisory roles as an Associate Editor for Mayo Clinic Proceedings and an Editorial Board member for the journals Frontiers in Pharmacology and Transplantation. G. Remuzzi reports Consultancy: Consulting fees: Alexion Pharmaceuticals, AstraZeneca Pharmaceuticals, Otsuka, and Silence Therapeutics; and Advisory or Leadership Role: member of numerous Editorial Boards of Scientific Medical Journals. All remaining authors have nothing to disclose.

Comment on

References

    1. Chen J-Z, Liang B. Cell therapies in diabetic kidney disease: is it time for clinical translation? J Am Soc Nephrol. 2023;34(12):2051–2052. doi:10.1681/ASN.0000000000000230 - DOI - PubMed
    1. Perico N Remuzzi G Griffin MD, et al. . Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM). J Am Soc Nephrol. 2023;34(10):1733–1751. doi:10.1681/ASN.0000000000000189 - DOI - PMC - PubMed
    1. Anders H-J, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361–377. doi:10.1038/s41581-018-0001-y - DOI - PubMed
    1. Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: a randomized, placebo-controlled, dose escalation study. EBioMedicine. 2016;12:263–269. doi:10.1016/j.ebiom.2016.09.011 - DOI - PMC - PubMed

Publication types

LinkOut - more resources